Literature DB >> 2565817

Biochemical and functional studies on EMD 49,980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems.

C A Seyfried1, H E Greiner, A F Haase.   

Abstract

EMD 49,980 proved to be a potent and selectively presynaptic D-2 dopamine receptor agonist in biochemical studies with rats. Thus, the gamma-butyrolactone-induced accumulation of dihydroxyphenylalanine, used as a presynaptic model, was antagonized with ED50 values of 0.29 and 0.09 mumol/kg in striatum and t. olfactorium, respectively, with high maximal effects. In contrast, striatal acetylcholine concentrations, reflecting actions at normosensitive postsynaptic D-2 receptors, were only moderately increased by about 30% over a dose range of 2.3-68 mumol/kg. In rats with unilateral nigrostriatal lesions, EMD 49,980 induced long-lasting contralateral turning, indicative of agonistic actions at denervated postsynaptic D-2 receptors. In addition, EMD 49,980 potently inhibited serotonin (5-HT) uptake in vitro and in vivo. Binding studies confirmed D-2 activity in the nM range but, similarly potent effects were observed at 5-HT1A binding sites. Measurement of 5-hydroxytryptophan (5-HTP) accumulation in the n. raphe revealed that, in vivo, the net effect of EMD 49,980 on 5-HT systems is an agonistic one. Control experiments indicate that inhibition of 5-HTP accumulation by EMD 49,980 is induced mainly via direct activation of 5-HT1A receptors, although some contribution due to 5-HT uptake inhibition is likely. Furthermore, results with various reference compounds make it unlikely that there are indirect effects, also via alpha 2-receptors in the models used and support the view that D-2 agonistic, 5-HT uptake inhibiting and 5-HT1A agonistic actions are independent properties of EMD 49,980.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565817     DOI: 10.1016/0014-2999(89)90651-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.

Authors:  Christoph van Amsterdam; Christoph A Seyfried
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

2.  Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.

Authors:  A F Haase; H E Greiner; C A Seyfried
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

3.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression.

Authors:  G Gründer; H Wetzel; E Hammes; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Roxindole, a potential antidepressant. I. Effect on the dopamine system.

Authors:  J Maj; K Kolodziejczyk; Z Rogóz; G Skuza
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Binding properties of the naturally occurring human 5-HT1A receptor variant with the Ile28Val substitution in the extracellular domain.

Authors:  M Brüss; M Bühlen; J Erdmann; M Göthert; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

7.  The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients.

Authors:  G Gründer; H Wetzel; A Hillert; E Jochum; C Hiemke; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

8.  Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.

Authors:  C Jaspers; G Benker; D Reinwein
Journal:  Clin Investig       Date:  1994-06

9.  Screening of Big Pharma's Library against Various in-house Biological Targets.

Authors:  Damijan Knez; Stanislav Gobec; Martina Hrast
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.